Amyloid ␤-protein (A␤), the major component of plaques in Alzheimer's disease, is a small hydrophobic protein that is carried on apolipoprotein E (ApoE)-and ApoJ-containing lipoprotein particles in plasma and cerebrospinal fluid (CSF). Microglia, the scavenger cells of the CNS, take up and degrade A␤ via lipoprotein receptors including scavenger receptors A and B, and possibly via other receptors. Lipoproteins, ApoE, and ApoJ influence the uptake and degradation of A␤ in vitro and in vivo. Differences in ApoE-E4, -E3, and -E2 isoforms with respect to A␤ binding to lipoproteins and delivery to cells, including microglia, may contribute to the increased risk of Alzheimer's disease for people with an APOE4 genotype and to risk reduction with APOE2. Microsc.
INTRODUCTION
Extracellular plaques of amyloid ␤-protein (A␤) and other associated proteins, distributed in specific brain regions, are a definitive characteristic of Alzheimer's disease, along with intracellular neurofibrillary tangles and loss of synapses. A␤ is a normally secreted byproduct of amyloid precursor protein metabolism that is normally rapidly degraded in a steady-state equilibrium with production (Savage et al., 1998) . Accumulations of aggregated A␤ in solution or deposited in plaques may be damaging to neurons, either by direct toxicity or through inflammatory, neurotoxic secretions of microglia cells. Accrual of plaques appears to reach an equilibrium during the disease, based in part on the demonstration by Hyman et al. (1993) that whereas a higher total area of A␤ immunoreactivity in temporal cortex distinguishes Alzheimer's disease from normal brain tissue, there is no correlation of amount of A␤ immunoreactivity with the duration of illness. Rather than plaque deposition continuing unchecked throughout the course of the disease, it appears that turnover occurs, so that as amyloid is deposited, a percentage of it is also removed. Consistent with the idea of turnover of plaque material during the disease, the form of A␤ found in plaques changes from predominantly A␤1-42 at early stages (diffuse plaques) to predominantly A␤1-40 at later stages (senile plaques) (Dickson, 1997; Nakamura et al., 1997) . In contrast, SDS insoluble, formic acid extractable amyloid, accumulates progressively and correlates with cognitive decline (Naslund et al., 2000) .
Microglia are likely agents of A␤ aggregation and amyloid removal. Activated, HLA-DR positive microglia are closely associated with plaques (Dickson et al., 1993; Mattiace et al., 1990; Styren et al., 1990; Tooyama et al., 1990 ; for review see Kalaria, 1999) . They are the phagocytic scavenger cells of the CNS, and they have multiple receptors for and take up both soluble and fibrillar A␤ in vitro (Ard et al., 1996; Cole et al., 1999; Paresce et al., 1996 Paresce et al., , 1997 Shaffer et al., 1995) . Similarly, in vivo after injection of A␤ into hippocampus, microglia loaded with A␤-immunoreactive material are found migrating toward ventricles and blood vessels (Frautschy et al., 1992) .
Increasing amyloid removal by microglia is a potential therapeutic target in Alzheimer's disease. This will require understanding of both microglial endocytosis and degradation of A␤, which may serve as a salutary clearance mechanism, and microglial inflammatory reactions to A␤ uptake. This review focuses on endocytosis and degradation of A␤ and its modulation by lipoproteins.
Lipoproteins are carriers of A␤ in biological fluids (Biere et al., 1996; Fagan et al., 1999; Koudinov et al., 1994 Koudinov and Koudinova, 1997; LaDu et al., 1995) , and this discovery has led to interest in the influence of lipoprotein on the microglial-A␤ interaction. The observed effects of the E4 allele of apolipoprotein E (APOE4) on risk for Alzheimer's disease, reducing the age of onset and increasing the amount of amyloid plaque burden in Alzheimer's brain tissue (Gearing et al., 1996; Mann et al., 1997; Schmechel et al., 1993) , could result directly from a lipoprotein role in A␤ trafficking and clearance.
In keeping with such a role, polymorphism in an ApoE receptor, LRP, has recently been shown to be associated with Alzheimer's disease (Hollenbach et al., 1998) . Lipoproteins may act at several levels as they affect aggregation of soluble A␤ into fibrils, binding of A␤ to cell surface receptors for endocytosis, lysosomal degradation of A␤, and the inflammatory response.
A␤ CIRCULATES BOUND TO LIPOPROTEINS
Like other nonpolar or hydrophobic peptides, A␤ in aqueous body fluids attaches to a carrier protein or lipoprotein particle for solubilization. Studies of A␤ in plasma by LaDu et al. (1995) and by Koudinov et al. (1994) showed that A␤ circulating in plasma is bound to lipoprotein particles, mainly to HDL. In one set of experiments in which radiolabeled A␤ was added to plasma, serum albumin as well as lipoprotein was found to bind A␤ (Biere et al., 1996) . Transthyretin has also been reported as an A␤ carrying protein (Schwarzman et al., 1994) . The discovery of lipoprotein carriers for A␤ was quickly followed by fractionation of CSF and identification of native A␤ in lipoprotein fractions, leading to the conclusion that A␤ circulates in CSF as a component of lipoprotein particles, mainly ApoE-and ApoJ-containing lipoproteins similar in size and density to plasma HDL .
Lipoprotein is produced by astrocytes, secreted as relatively lipid-poor apolipoprotein and lipid particles . A␤ itself in a transfected cell line is secreted with lipid as part of a lipoprotein particle (Koudinov and Koudinova, 1997) . Therefore, A␤ is most likely bound to lipoprotein in brain parenchyma, as in CSF. This is an important point since in Alzheimer's disease the level of soluble A␤1-42 in brain tissue is about 50 times greater than that in CSF (Kuo et al., 1996) . Furthermore, increases in levels of A␤ in Alzheimer's relative to control brains are found in brain tissue rather than in CSF (Kuo et al., 1996; Tabaton et al., 1994; Wang et al., 1999) .
Within lipoproteins A␤ is bound to ApoJ and to ApoE Golabek et al., 1995; Matsubara et al., 1996; Wisniewski et al., 1993) as well as to lipids (Koudinov et al., 1998) . Binding of synthetic A␤ to ApoJ in its native lipidated form prevents fibril formation in vitro (Matsubara et al., 1996) . This observation heightened interest in the possibility that APOE allelic differences in risk for Alzheimer's disease might be based on differences in direct interaction between ApoE and A␤.
A␤ CAN BE ENDOCYTOSED VIA MICROGLIAL LIPOPROTEIN RECEPTORS
Activated microglia express most if not all macrophage cell surface markers including lipoprotein receptors. The standard tool for identifying microglia is a fluorescently tagged acetylated LDL probe for scavenger receptor; they also have LRP, LDL receptor, and presumably other macrophage receptors. These receptors allow macrophages to play a major role in lipid uptake, especially after injury. Therefore, microglia can be expected to avidly take up ApoE-containing lipoprotein particles (with or without A␤) after brain injury, when the APOE4-related risk of A␤ deposits dramatically increases (Nicoll et al., 1995) .
The macrophage scavenger receptor (class A, Yamada et al., 1998 ), which appears on microglia in response to activation (Bell et al., 1994) and in Alzheimer's plaques (Christie et al., 1996; Honda et al., 1998) , binds and internalizes fibrillar A␤ in vitro (Chu et al., 1998; El Khoury et al., 1996; Paresce et al., 1996 Paresce et al., , 1997 . Binding of A␤ fibrils to scavenger receptor stimulates microglial secretion of reactive oxygen species, which can be blocked by a synthetic peptide competitively inhibiting binding to the receptor (El Khoury et al., 1996) . Uptake of A␤ microaggregates or fibrils is also partially inhibited by the scavenger receptor ligands acetylated LDL, maleylated bovine serum albumin, or fucoidan (Chu et al., 1998; Paresce et al., 1996) .
Scavenger receptors of class B (SR-B) were also investigated by Paresce et al. (1996) , using CHO cells transfected with the hamster SR-B1 receptor. These receptors also mediated uptake of A␤ microaggregates, which was competitively inhibited by acetylated LDL, maleylated bovine serum albumin, or, to a lesser extent, fucoidan. Ligands internalized via SR-B1, such as HDL, acetylated LDL, ␤-VLDL, and lipoprotein-bound ApoE, instead of entering the lysosomal degradation pathway, may alternatively be sequestered in surfaceconnected compartments formed by deep invaginations of the macrophage plasma membrane (Kruth et al., 1995) . A␤ enters surface-connected compartments in microglia ( Fig. 1 ; Cole et al., 1999) . Entry into this compartment may delay proteolytic degradation and facilitate resecretion of undegraded protein. In fact, an exceptional function of SR-B1 is that it mediates delivery of HDL lipids to cells without entry of the associated apolipoproteins into the coated pit-endosome-lysosome pathway (Acton et al., 1996) .
Apolipoproteins that are delivered into the lysosomal pathway by other receptors such as class A scavenger receptors, LDL receptor, or LRP may either separate from the lipid moiety, as ApoE does, or, like ApoB, remain attached to lipid in lysosomes as further separation of lipid and protein occurs. In our electron microscopical studies of cellular internalization of A␤, immunolabeled A␤ is frequently seen attached to lipid in lysosomes ( Fig. 1 ; Cole et al., 1999) .
Cells may also resecrete intact A␤ after uptake, as first convincingly shown by Chung et al. (1999) . In agreement with earlier reports (Ard et al., 1996; Cole et al., 1999; Frackowiak et al., 1992; Paresce et al., 1996 Paresce et al., , 1997 Shaffer et al., 1995) , the authors found that microglia accumulated fibrillar A␤. While some A␤ was degraded, a substantial proportion was retained undegraded for up to 7 days, and a part of the ingested fibrillar A␤ was resecreted into the chase medium for up to 12 days after loading for 1 hour. Soluble A␤, in contrast to fibrillar, was taken up by microglia and almost entirely resecreted into the medium over a period of hours, with little degradation. Uptake of soluble A␤ was not saturable and was not competitively inhibited by scavenger receptor ligands; therefore, it appeared to occur by non-receptor-mediated fluid-phase endocytosis. Like fibrillar A␤, soluble A␤ appeared to enter lysosomes, based on light microscopic colocalization with fluorescently labeled ␣2-macroglobulin.
A␤ entering cells via lipoprotein receptors may ultimately affect the lipid content of membranes. Lysosomal membrane integrity was compromised by cellular uptake of A␤1-42, but not A␤1-40, in a cell line , and in synaptosome preparations treated with A␤ in vitro, changes in membrane phospholipids were observed (Mattson et al., 1998) . A␤ has been shown to increase free cholesterol in neurons, altering trafficking of intracellular transport vesicles (Liu et al., 1998) . The increase in cholesterol, due to A␤ or lipopro-tein mediated cholesterol uptake into surface-connected compartments (caveolae) can alter APP processing by reducing alpha secretase activity (Bodovitz et al., 1996) and increasing A␤ generation (Simons et al., 1998) . A␤1-42 at less than nanomolar concentrations activates the enzyme phospholipase A 2 in vitro, with the effect dependent on the composition of the phospholipid substrate (Lehtonen et al., 1996) . In the HepG2 cell line, A␤1-40 decreases synthesis of esterified cholesterol and phospholipids . Phospholipid changes also occur in brain tissue from Alzheimer's disease cases, with a reduction in longchain fatty acids in phosphatidylcholine and phosphatidylethanolamine (Corrigan et al., 1998) .
In addition to lipoprotein receptor binding, A␤ has also been shown to bind to the RAGE receptor (receptor for advanced glycation end products, a member of the immunoglobulin superfamily) on microglia, neurons, and endothelial cells in a dose-dependent manner (Yan et al., 1996) . Soluble A␤ or A␤ immobilized on a substrate binds to RAGE; it does not appear to be a receptor for fibrils. However, A␤ activation of immortalized BV-2 microglia, measured by stimulation of cell migration, secretion of TNF␣, increase of TNF␣ mRNA, and activation of NF-B, could be inhibited by anti-RAGE F(ab') 2 . Soluble A␤, but not fibrillar, is also reported to bind to the serpin-enzyme complex receptor (receptor for serine protease inhibitor-enzyme complexes) (Boland et al., 1995) .
A caveat about receptors comes from the studies of signal transduction mechanisms by McDonald et al. (1997 McDonald et al. ( , 1998 . These investigators confirmed previous reports of activation of microglia by fibrillar A␤, and in addition assayed not only inflammatory mediators (superoxide radicals and IL-1␤) secreted by the cells but also signal transduction molecules of the mitogen-activated protein kinase superfamily. They found that whereas fibrillar A␤ activated kinases in this cascade, other scavenger receptor ligands and RAGE ligands were ineffective or much less effective, indicating that A␤ acted at least partially through a different, unknown receptor pathway. These experiments used a large amount of A␤, 50 m, leaving open the possibility that phagocytosis of fibrils might have contributed to activation of the cells in a way that was chemically nonspecific (Yates et al., 1999) .
LIPOPROTEIN DEPENDENCE OF A␤-RECEPTOR INTERACTION IS UNTESTED
Studies of A␤ binding to microglial receptors are difficult to interpret for at least three reasons. First, A␤ is almost always presented in free form rather than associated with a lipoprotein or other carrier as it is in CSF and probably in brain. Indeed, this was the method used in all of the studies by El Khoury et al. (1996) , Paresce et al. (1996 Paresce et al. ( , 1997 , Chung et al. (1999) , Yan et al. (1996) , Boland et al. (1995 ), and McDonald et al. (1997 discussed above. Second, even though exogenous lipoprotein is not added to the incubation medium, microglia may secrete lipoprotein or ApoE; this secretion may vary from experiment to experiment and it is not controlled for. Although astrocytes are believed to be the major producers of ApoE in the CNS, macrophages are known to have robust ApoE synthesis (Deng et al, 1995) , and microglia in culture synthesize as much ApoE as astrocytes ( fig. 6 in Cole et al., 1999; unpublished observations) . The major pool of macrophage ApoE is retained on the cell surface bound to heparan sulfate proteoglycans (Lucas and Mazzone, 1996) . This ApoE can be secreted or reinternalized, either directly or via higher affinity receptors on the cell surface such as LRP, LDL receptor, or scavenger receptors. Potentially, then, endogenous ApoE may affect A␤ binding to microglia in vitro.
Third, lipoprotein receptors share a common lowaffinity co-receptor, cell-surface heparan sulphate proteoglycan (HSPG). Cell surface HSPGs are now thought to initially bind lipoproteins (Mahley, 1996) , serving as high capacity, low affinity receptors for ApoE-containing particles, which are then passed on to LRP, LDL, scavenger or other high affinity receptors. This trafficking is ApoE isoform-dependent so that in tests with neuronal cells, ApoE3 accumulates 3-6-fold greater than ApoE4 (Mahley, 1996 (Mahley, , 1997 Mahley et al., 1996; Weisgraber and Mahley, 1996) . New data on biochemical differences show that ApoE3 and E4 differ in that Arg 61 forms an intramolecular salt bridge in E3, but not in E4 (2). This appears to result in differential association with cell surface HSPGs. Cell surface HSPGs are essential for selective accumulation of ApoE via lipoprotein receptors and may also regulate accumulation of A␤ bound to ApoE and subsequent uptake and degradation or resecretion and deposition.
LIPOPROTEINS AFFECT DEGRADATION OF
A␤ BY MICROGLIA IN VITRO Considering that there is good evidence that A␤ in CSF is carried by lipoprotein, it is surprising that so few studies of A␤ cell binding and degradation have incorporated lipoprotein or serum into the incubation medium. We have found profound differences in microglial uptake and degradation of A␤1-42 depending on the presence or absence of lipoprotein in the incubation medium (Cole et al., 1999) . The different lipoproteins showed distinct differences in the ultimate amount of the A␤ removed from the medium, accumulated in the cells or degraded.
Lipoproteins in 2% fetal bovine serum or human plasma HDL increased microglial removal of A␤ from the medium, compared to control medium containing 0.1% bovine serum albumin without exogenous lipoprotein (Table 1) . At the same time that A␤ was removed from the medium, very little accumulated in the cell pellet, suggesting degradation was stimulated by these lipoproteins. Plasma HDL has been used as a model for CSF lipoproteins in some of our own and other studies because of their similarities including particle size and apolipoprotein content (Borghini et al., 1995; Pitas et al., 1987) . However, there are functional differences between them, as noted by Rebeck et al. (1998) , who observed that CSF lipoprotein, but not plasma HDL, competitively inhibits LDL degradation by fibroblasts. Whether CSF HDL also stimulates A␤ degradation remains unknown.
The apolipoproteins reconstituted in liposomes did not mimic complete HDL purified from pooled human plasma, which is not surprising as HDL (unlike ApoE or ApoJ) is known to be a good scavenger receptor B1 ligand on macrophage lineage cells. Nevertheless, use of the liposomes did show differences between ApoE isoforms, as displayed in Table 1 . In contrast to plasma HDL, dimyristoylphosphatidylcholine liposomes with reconstituted ApoJ and recombinant ApoE2, -E3, or -E4 decreased A␤ removal from the media and increased total A␤ remaining, suggesting reduced A␤ clearance. These results were taken from Western blotting, which allowed densitometric comparisons of A␤ monomer and aggregates remaining in the medium at the end of the incubation and A␤ accumulated by the cells. Simultaneous reductions in both pools indicated net loss, which was interpreted as degradation based on sensitivity to protease inhibitors.
Compared to ApoE3 and ApoE2, ApoE4 resulted in more A␤ removal from the medium. This is consistent with the reduced affinity of ApoE4 for A␤, since it resulted in a clearance pattern more similar to that seen for free A␤. ApoE3 and ApoE2 had equivalent levels of A␤ removed from the medium, but with ApoE2 there was less accumulation in the cell pellet, indicating more effective net A␤ degradation, a phenomenon that could help account for reduced A␤ deposits with APOE2 genotype.
In addition to microglia, neurons and smooth muscle cells also respond to the combination of A␤ with lipoproteins. In rat hippocampal neurons in vitro, artificial liposomes containing ApoE4 increased the net internalization of A␤-40, compared to ApoE3-containing liposomes (Beffert et al., 1998) . In the same study, A␤ increased uptake of ApoE by neurons, with a greater increase in uptake of ApoE4 than of ApoE3 liposomes; however, ApoE3 was degraded more effectively than ApoE4, and degradation was not altered by A␤.
In smooth muscle cells, lipoproteins from either human serum or CSF promoted uptake of A␤1-40 and A␤1-42; A␤ internalization was reduced with lipoprotein-deficient serum (Urmoneit et al., 1997) . Lipoprotein receptors on these cells appear to mediate A␤ uptake, since it can be inhibited by the 39 kDa receptor-associated protein that blocks LRP and other lipoprotein receptors. Furthermore, A␤ colocalizes im- 
1 ϩ ϭ positive result in the parameter indicated; ϩϩ ϭ larger positive result than ϩ; Ͻ ϭ less than seen with A␤ alone, without lipoprotein; ϽϽ ϭ less than Ͻ; -ϭ values not measured for comparison with this set of experiments.
munocytochemically with both ApoE and LRP. Degradation of A␤ was not addressed in this study. ApoJ as well as ApoE binds to A␤ and promotes its uptake via the ApoJ receptor LRP-2 followed by lysosomal degradation (Hammad et al., 1997) . In those experiments, formation of the ApoJ/A␤ complex was necessary for LRP-2 receptor recognition of A␤. In our microglia experiments described in Table 1 , particles with ApoJ alone resulted in greater A␤ clearance (removal from the medium, without accumulation in the cells) than particles with both ApoJ and any of the ApoE isoforms (Cole et al., 1999) . In the absence of ApoE, ApoJ may contribute to more effective degradation of A␤, consistent with observations of reduced plaque formation in PDAPP transgenics crossed with APOE null mice (Bales et al., 1997) .
LIPOPROTEINS AND A␤ DEGRADATION
IN VIVO Although a number of proteases can contribute to A␤ degradation in vitro, there is very limited information about what regulates A␤ degradation in vivo. Evidence for a role of matrix metalloproteases has been developed, but remains inconclusive (Lim et al., 1997) . Results of metabolic labeling studies in APP transgenic mice with a 30-minute labeling pulse suggested a rough estimate of t1/2 for the immunoprecipitable pool of endogenous A␤ between 1 and 2.5 hours based on assumptions of a steady state equilibrium with the rate of synthesis (Savage et al., 1998) . Injection of small amounts of soluble radiolabeled A␤ into rat hippocampus is followed by a rapid degradation of the A␤ by extracellular proteases, including the metalloprotease, neprilysin (Iwata et al., 2000) . The t1/2 for A␤ in these experiments is less than 1 hour. Chronic inhibition of neprilysin results in A␤ deposit formation in rat brain demonstrating the physiological importance of this pathway. Thus, A␤ is normally rapidly degraded and this rapid degradation plays a critical role in preventing A␤ deposit formation.
Interest in A␤ degradation has increased dramatically following reports of a promising A␤ vaccine. Immunization of plaque-forming APP transgenic mice with aggregated A␤ and adjuvant can both prevent A␤ deposit formation and actually reduce previously formed A␤ deposits . This report links the efficacy of vaccination to the formation of high titers of anti-A␤ antibodies and the promotion of increased A␤ clearance by Fc receptor-bearing microglia and receptor-mediated endosomal/lysosomal clearance. Increasing A␤ clearance thus shows real therapeutic potential. However, additional vaccine effects are possible, for example, anti-A␤ antibodies are also capable of directly inhibiting A␤ aggregation in vitro (Solomon et al., 1996) .
Like A␤ antibodies, lipoproteins are relatively high affinity A␤ binding proteins with Kd in the nanomolar range capable of regulating A␤ aggregation and receptor-mediated A␤ degradation. Further, unlike Fc receptor concentrated on microglia, multiple lipoprotein receptors linked to endocytosis and lysosomal degradation are present not only on microglia but other cell types including neurons and astrocytes. The lower affinity of lipoproteins relative to antibodies may be compensated by CNS micromolar levels of lipoproteins that are likely much higher than the level of A␤ antibodies reaching the brain, which have relatively poor access to the CNS. Thus, the normal regulation of A␤ aggregation and degradation by CNS lipoproteins may be analogous to that of antibodies in preventing self-aggregation and promoting receptor-mediated endocytosis and clearance.
APOE CONTROLS AMYLOID DEPOSITION
IN VIVO AND IN VITRO Whether via directly regulating degradation or indirectly regulating degradation by promoting aggregation and deposition, ApoE clearly controls the ultimate fate of A␤ in vivo. Whereas ApoE had been previously discovered in A␤ deposits (Namba et al., 1992) , the identification of the APOE4 allele as a genetic risk factor for AD and the APOE2 allele as protective (Corder et al.,1994; Saunders et al., 1993) demonstrated some important role for ApoE in the pathogenesis of AD (Hyman, 1997; Mahley, 1997) . ApoE deposits are reported to be numerous, not entirely coincident with A␤ and to occur at an early stage in diffuse plaque formation (Nishiyama et al., 1997) . However, the ApoE4 isoform consistently increases A␤1-40 (not 1-42) deposition (Gearing et al., 1996; Ishii et al., 1997; Mann et al., 1997) . Direct evidence for a major role in controlling amyloid deposition comes from crosses between APOE knockout mice and amyloid plaque-forming APP transgenics. This work has provided compelling evidence that reducing mouse ApoE dramatically limits A␤ deposition and amyloid plaque formation (Bales et al., 1997) . Crosses of human APOE allele transgenics with APP transgenics on a null background have further demonstrated that ApoE expression and isoform subtype influence amyloid deposit formation, but at early stages of A␤ deposition, human ApoE expression actually reduced deposits in the hippocampus ).
There are two major theories to account for these observations. The first theory argues that ApoE4 directly promotes ␤-amyloid formation and is based on observations showing: (1) ApoE is found in many types of amyloid (Castano et al., 1995a) and, (2) the relative speed and extent of A␤ assembly into amyloid fibrils in vitro can be controlled by the addition of purified (and delipidated and therefore denatured) ApoE (Castano et al., 1995b; Ma et al., 1994; Sanan et al., 1994; Wisniewski et al., 1994) . The amyloidogenic effects were in the order ApoE4ϾApoE3ϾApoE2. By itself, this theory is seemingly in conflict with the data showing increased ApoE4 actually reduced hippocampal A␤ deposition at initial stages , but the early hippocampal deposits may not be amyloid, but preamyloid. The theory is consistent with new data from the same group showing ApoE4 later increases A␤ deposition (see review by Fagan et al., pages xxx-xxx, this issue) and observations showing overexpression of human ApoE4 in APPsw transgenics on a mouse APOE background results in accelerated A␤ deposition (Carter et al., 1999) .
A second theory is based on the finding that A␤ binds ApoE, ApoJ, and other lipoproteins suggesting these particles serve as chaperones or carriers for A␤ (Castano et al., 1995b; Ghiso et al., 1993; Koudinov et al., 1994; Wisniewski et al., 1993; Zlokovic et al., 1994) . Native (lipidated) ApoE4 binds A␤ with 2-3 times lower affinity than native ApoE3 or ApoE2 (Aleshkov et al., 1997; LaDu et al., 1995; Yang et al., 1997) . In this view, the higher affinity ApoE3 binding to A␤ is protective by preventing self-aggregation leading to amyloid formation and instead promoting receptor-mediated endocytosis followed by endosomal/ lysosomal degradation. The defect in ApoE4 leading to reduced A␤ binding could result in reduced endosomal/lysosomal degradation or extracellular degradation of A␤ on ApoE and enhanced A␤ aggregate formation.
Experimental evidence supporting both mechanisms can be obtained depending on important details of how experiments are performed. Injection of small amounts of soluble radiolabeled A␤ into rat hippocampus is followed by a rapid degradation of the A␤ by extracellular proteases (Iwata et al., 2000) . Rapid disappearance of A␤ (detected by sandwich ELISA) also occurs after intrahippocampal injection of 400 ng of A␤1-40 into WT and APOE knockout brains with a small pool of significantly more A␤ remaining in the wildtype ApoE producing animals 2.5 hours after injection (Chu et al., 1997) . Similar data have been obtained in a separate set of experiments injecting 1-2 g of A␤1-40 and assaying 30 minutes after injection (Chu et al., unpublished data) . These results suggest that A␤ binding by the wild-type mouse ApoE delays the rapid A␤ degradation of a small fraction of the A␤ by extracellular proteases, notably neprilysin. Under these conditions (using low levels of A␤1-40 and no salt) self-aggregation is probably not a key factor determining the fate of the soluble A␤1-40. The kinetics of degradation of ApoE-A␤ complexes may take longer because of the additional steps required for internalization and be dependent on the levels of cellular lipoprotein receptors such as LRP and LDL compared with extracellular matrix heparan sulfate proteoglycans or similar ApoE binding proteins.
With a different paradigm, Permanne and coworkers injected radiolabeled A␤ intraventricularly and found rapid clearance with no difference between APOE4, E3, and APOE knockout animals (Permanne et al., 1999) . Much of this i.c.v. injected A␤ is not degraded, but rapidly leaves the brain (Ghersi-Egea et al., 1996) . They also injected into the amygdala using 2 nm (10 g) of A␤1-42 in 1.5 l (a level resulting in A␤ aggregation) in APOE knockout mice and transgenics expressing GFAP driven human ApoE3 or ApoE4. Animals were examined at 1 month for A␤ immunostaining and Congo red labeled amyloid deposits. Under these conditions, the amount of amyloid remaining was similar for APOE3 and APOE4 transgenics, but the APOE knockouts had significantly more. These results were interpreted to suggest a role for ApoE in both promoting A␤ clearance and/or promoting amyloid formation. One key factor determining the effect of ApoE appears to be whether or not there are robust A␤ aggregate forming conditions.
Depending on experimental detail, ApoE isoform differences in interactions with A␤ have also been quite varied in vitro (Table 2) .
These conflicting data show that depending on the A␤ and ApoE preparations and the assay used, one gets varying results. ApoE4 directly promotes (while ApoE2 inhibits) fibril formation (Table 2) Wisniewski et al., 1994) in experiments using high levels of ApoE and A␤ prepared from acid (HCL or TFA), which results in many seeds and rapid aggregation. In contrast, inhibition of amyloid formation was obtained with lower levels of ApoE and A␤ prepared out of DMSO or HFIP, which resulted in fewer seeds and slower aggregation. ApoE isoform differences in A␤ binding are radically altered by delipidation and are presumably conformation-dependent. It is widely believed that interactions in the absence of lipid are questionably relevant in lipid-rich CNS. However, Permanne et al. (1999) have recently presented evidence that lipidated (native) ApoE isoforms have similar isoform-dependent effects on beta-amyloid formation in vivo as those seen with delipidated ApoE isoforms in vitro.
Because ApoE is likely to be lipidated in vivo and lipidation alters the affinity for A␤, the results with lipidated ApoE are likely more relevant to its function as an A␤ carrier in vivo. Native, lipidated ApoE2 or E3 binds A␤ far better than ApoE4 (LaDu et al., 1994; Yang et al., 1997) . However, the formation of SDS stable complexes is not necessarily physiologically relevant and one would like to see gel filtration assays in native buffer using lipidated ApoE to firmly establish the order of affinity for A␤ as E2ϾE3ϾE4. This difference in affinity may allow ApoE2 or E3 to inhibit A␤ fibrillogenesis by binding free A␤ and inhibiting aggregation. Consistent with this idea, lipidated ApoE3 (not E4) protects target cells from toxicity caused by aggregating A␤ (Farhangrazi et al., 1997; Jordá n et al., 1998) . ApoE4 or E4 particles with other apolipoproteins may also interact differently with receptors (LDL, LRP, HSPG) (Rebeck et al., 1995) or lipoprotein particles. For example, an ApoE isoform difference in HDL trafficking (Gregg et al., 1986; Hayek et al., 1994; Maz- Yang et al. (1997) ; Aleshkov et al. (1997) zone and Reardon, 1994) might result in an additional loss of A␤ trafficking function. As discussed earlier, A␤ in plasma and CSF is associated with HDL particles containing ApoE and ApoJ (Castano et al., 1995b; Ghiso et al., 1993; Koudinov et al., 1994; Wisniewski et al., 1993; Zlokovic et al., 1994) . SDS stable A␤ dimers accumulate in normal aging brain and may be an initial phase of amyloid deposition or clearance or related to neurotoxicity (Enya et al., 1999) . Soluble dimer levels were much lower in PDAPP mice, which show limited neuron loss, but extensive deposits. Soluble A␤ dimer-ApoE complexes have been purified from AD brain while complexes with other A␤ binding proteins were not detected (Permanne et al., 1997) . Another group found that soluble ApoE/A␤ complexes were significantly higher in normal brain than AD brain (Russo et al., 1998) . They also reported that the A␤ in the soluble complexes with ApoE running on SDS gels at ϳ40 kD was more susceptible to proteinase K digestion in total homogenates. This data would be consistent with a role for ApoE in promoting the solubilization and clearance of monomeric A␤ and dimers in normal brain as in the early stages of deposition in PDAPP transgenics expressing human ApoE4 or E3 . In contrast, in conditions with many preformed seeds and rapidly aggregating levels of amyloid (e.g., AD cases and older APP transgenic mice), the role of ApoE4 may switch to pro-amyloidogenic. These data are consistent with the variable results with ApoE and A␤ in vitro reviewed above.
In conclusion, ApoE isoforms can influence A␤ degradation by multiple mechanisms through differential effects on A␤ binding, lipoprotein trafficking followed by receptor-mediated endocytosis, and direct effects on amyloid formation and susceptibility to proteolytic degradation.
SUMMARY
A␤ in vivo circulates bound to lipoprotein particles. Evidence from microglial cultures, from injection of A␤ into rat brain, and from A␤ deposition in transgenic and APOE knockout mice shows that lipoprotein affects clearance of A␤ from the cellular environment, and that different isoforms of ApoE incorporated into lipoprotein also affect A␤ clearance differentially. This is a mechanism by which allelic variation in APOE genotype can influence an individual's risk of Alzheimer's disease, since there is a relationship, though not a direct correspondence, between amyloid plaque formation and Alzheimer's dementia.
